Suppr超能文献

现实世界中NAFLD组织学诊断的患者决定因素:一项TARGET-NASH研究

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.

作者信息

Barritt A Sidney, Watkins Stephanie, Gitlin Norman, Klein Samuel, Lok Anna S, Loomba Rohit, Schoen Cheryl, Reddy K Rajender, Trinh Huy Ngoc, Mospan Andrea R, Vos Miriam B, Weiss L Michael, Cusi Kenneth, Neuschwander-Tetri Brent A, Sanyal Arun J

机构信息

Division of Gastroenterology and HepatologyUNC Liver CenterUniversity of North Carolina at Chapel HillChapel HillNCUSA.

Target RWEDurhamNCUSA.

出版信息

Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.

Abstract

Much of the current data on nonalcoholic fatty liver disease (NAFLD) are derived from biopsy-based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study was to determine patient factors predictive of histologic versus empiric clinical diagnosis of NAFLD in real-world practice. Adults from TARGET-NASH were included in this study. Descriptive statistics are provided for the cohort and compare the characteristics of histologic NAFLD versus patients with clinically diagnosed NAFLD, followed by logistic regression and machine-learning models to describe predictors of liver biopsy. The records of 3,474 subjects were analyzed; median age was 59 years, 59% were female, 75% were White, and median body mass index was 32 kg/m. Using histologic and/or clinical criteria, a diagnosis of nonalcoholic steatohepatitis was made in 37%, and cirrhosis in 33%. Comorbid conditions included cardiovascular disease (19%), mental health diagnoses (49%), and osteoarthritis (10%). Predictors of a biopsy diagnosis included White race, female sex, diabetes, and elevated alanine aminotransferase (ALT). ALT increased the odds of liver biopsy by 14% per 10-point rise. Machine-learning analyses showed non-White patients with ALT <69 had only a 0.06 probability of undergoing liver biopsy. ALT was the dominant variable that determined liver biopsy. : In this real-world cohort of patients with NAFLD, two-thirds of patients did not have a liver biopsy. These patients were more likely to be non-White, older, with a normal ALT, showing potential gaps in or knowledge about this population.

摘要

目前关于非酒精性脂肪性肝病(NAFLD)的许多数据都来自基于活检的研究,这类研究可能会引入确诊和选择偏倚。选择患者进行肝活检对临床实践以及所报告的NAFLD流行病学有影响。本研究的目的是确定在实际临床中能够预测NAFLD组织学诊断与经验性临床诊断的患者因素。本研究纳入了来自TARGET - NASH研究中的成年患者。提供了该队列的描述性统计数据,并比较了组织学确诊的NAFLD患者与临床诊断为NAFLD患者的特征,随后采用逻辑回归和机器学习模型来描述肝活检的预测因素。分析了3474名受试者的记录;中位年龄为59岁,59%为女性,75%为白人,中位体重指数为32kg/m²。根据组织学和/或临床标准,37%的患者被诊断为非酒精性脂肪性肝炎,33%的患者被诊断为肝硬化。合并症包括心血管疾病(19%)、精神健康诊断(49%)和骨关节炎(10%)。活检诊断的预测因素包括白人种族、女性、糖尿病和丙氨酸氨基转移酶(ALT)升高。ALT每升高10个单位,肝活检的几率增加14%。机器学习分析显示,ALT<69的非白人患者接受肝活检的概率仅为0.06。ALT是决定肝活检的主要变量。在这个NAFLD患者的实际队列中,三分之二的患者未进行肝活检。这些患者更可能是非白人、年龄较大、ALT正常,这表明在这一人群中存在潜在的差距或认知不足。

相似文献

1
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.
Hepatol Commun. 2021 Feb 21;5(6):938-946. doi: 10.1002/hep4.1689. eCollection 2021 Jun.
2
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Cochrane Database Syst Rev. 2013 Dec 27;2013(12):CD008623. doi: 10.1002/14651858.CD008623.pub2.
3
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Jul 19;7(7):CD013157. doi: 10.1002/14651858.CD013157.pub2.
4
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Health Technol Assess. 2011 Nov;15(38):1-110. doi: 10.3310/hta15380.
5
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
6
Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Jun 11;6(6):CD013156. doi: 10.1002/14651858.CD013156.pub2.
7
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 30;3(3):CD011640. doi: 10.1002/14651858.CD011640.pub2.

引用本文的文献

2
Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database.
Adv Ther. 2025 Feb;42(2):1165-1195. doi: 10.1007/s12325-024-03085-4. Epub 2024 Dec 30.
5
Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults.
Arthritis Res Ther. 2024 Jan 31;26(1):40. doi: 10.1186/s13075-024-03272-2.
6
Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
Metabolites. 2024 Jan 8;14(1):40. doi: 10.3390/metabo14010040.
7
A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease.
Ann Hepatol. 2024 Mar-Apr;29(2):101278. doi: 10.1016/j.aohep.2023.101278. Epub 2023 Dec 20.
8
Predictive Algorithm for Hepatic Steatosis Detection Using Elastography Data in the Veterans Affairs Electronic Health Records.
Dig Dis Sci. 2023 Dec;68(12):4474-4484. doi: 10.1007/s10620-023-08043-8. Epub 2023 Oct 21.
9
Poor Performance of Non-invasive Tests for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: A Multicentric Asian Study.
Dig Dis Sci. 2023 Dec;68(12):4485-4498. doi: 10.1007/s10620-023-08085-y. Epub 2023 Sep 21.
10
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies.
Ann N Y Acad Sci. 2023 Aug;1526(1):16-29. doi: 10.1111/nyas.15012. Epub 2023 Jul 3.

本文引用的文献

4
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Contemp Clin Trials. 2017 Oct;61:33-38. doi: 10.1016/j.cct.2017.07.015. Epub 2017 Jul 19.
6
7
Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study.
PLoS One. 2016 Sep 6;11(9):e0161821. doi: 10.1371/journal.pone.0161821. eCollection 2016.
8
Diagnosed and Undiagnosed Diabetes Prevalence by County in the U.S., 1999-2012.
Diabetes Care. 2016 Sep;39(9):1556-62. doi: 10.2337/dc16-0678.
9
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Hepatology. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785. Epub 2016 Sep 26.
10
Practice patterns in NAFLD and NASH: real life differs from published guidelines.
Therap Adv Gastroenterol. 2016 Jan;9(1):4-12. doi: 10.1177/1756283X15611581.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验